Mesoblast, FDA agree on marketing application for cell therapy

JHVEPhoto

Mesoblast (NASDAQ:MESO) added ~13% in the morning hours on Tuesday after the Australian biotech said that the FDA agreed with the company regarding key components of a marketing application (BLA) planned for its cell therapy Revascor (rexlemestrocel-L).

The announcement comes